Clinical trial
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who…
NCT00115167 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00115167 |
|---|---|
| Title | A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study |
| Official title | A Multicenter, Randomised, Double-Blind, Placebo-Controlled Roll Over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Cancer |
| Intervention type | Drug |
| Interventions | Placebo, Darbepoetin alfa |
| Enrollment | 371 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jun 22, 2005 |
| Last update posted | May 11, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: